Efficacy of sertraline against Trypanosoma cruzi: an in vitro and in silico study

Ferreira, Daiane DiasMesquita, Juliana ToniniSilva, Thais Alves da CostaRomanelli, Maiara MariaBatista, Denise da Gama JaenSilva, Cristiane França daGama, Aline Nefertiti Silva daNeves, Bruno JuniorMelo-Filho, Cleber CamiloSoeiro, Maria de Nazare CorreiaAndrade, Carolina HortaTempone, Andre Gustavo

Background: Drug repurposing has been an interesting and cost-effective approach, especially for neglected diseases, such as Chagas disease. Methods: In this work, we studied the activity of the antidepressant drug sertraline against Trypanosoma cruzi trypomastigotes and intracellular amastigotes of the Y and Tulahuen strains, and investigated its action mode using cell biology and in silico approaches. Results: Sertraline demonstrated in vitro efficacy against intracellular amastigotes of both T. cruzi strains inside different host cells, including cardiomyocytes, with IC50 values between 1 to 10 M, and activity against bloodstream trypomastigotes, with IC50 of 14 M. Considering the mammalian cytotoxicity, the drug resulted in a selectivity index of 17.8. Sertraline induced a change in the mitochondrial integrity of T. cruzi, resulting in a decrease in ATP levels, but not affecting reactive oxygen levels or plasma membrane permeability. In silico approaches using chemogenomic target fishing, homology modeling and molecular docking suggested the enzyme isocitrate dehydrogenase 2 of T. cruzi (TcIDH2) as a potential target for sertraline. Conclusions: The present study demonstrated that sertraline had a lethal effect on different forms and strains of T. cruzi, by affecting the bioenergetic metabolism of the parasite. These findings provide a starting point for future experimental assays and may contribute to the development of new compounds.(AU)

1. Treatment
2. Trypanosoma cruzi
3. Drug repositioning
4. Drug
5. Sertraline
6. Drug repurposing